Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1CD20-positive Hematological Malignancies 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Exercise 9Standard of Care 5trametinib 3tislelizumab 3Radiotherapy 3Radiosurgery 3Palliative Care 3Paclitaxel 3Gemcitabine 3Carboplatin 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2cemiplimab 2Therapeutics 2Surveys and Questionnaires 2Resistance Training 2Oxaliplatin 2Maintenance 2Immune Checkpoint Inhibitors 2Drug Therapy 2Cisplatin 2Anastrozole 2vedolizumab 1toripalimab 1surufatinib 1sparsentan 1sintilimab 1semaglutide 1posaconazole 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms × Injections, Subcutaneous × Clear all
NCT07603479 2026-05-22

A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Jecho Biopharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
14 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡